Drug
Domvanalimab
Domvanalimab: highest development phase Phase 3, developed by Arcus Biosciences, AstraZeneca, Gilead Sciences. 5 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Arcus Biosciences, AstraZeneca, Gilead Sciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| Domvanalimab NCT05568095 | Phase 3 | Advanced Upper Gastrointestinal Tract Adenocarcinoma |
| Domvanalimab NCT05211895 | Phase 3 | Non-Small Cell Lung Cancer |
| Domvanalimab NCT06727565 | Phase 2 | Head and Neck Squamous Cell Carcinoma |
| Domvanalimab NCT04736173 | Phase 2 | Non Small Cell Lung Cancer |
| Domvanalimab NCT05329766 | Phase 2 | Gastrointestinal Tract Malignancies |
Latest
Follow Domvanalimab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.